Bird & Bird Advises Pharmagene on Human Gene Expression Database Agreement


Pharmagene to provide Schering-Plough Research Institute with access to Pharmagene TargetEvaluator®

International law firm Bird & Bird has recently advised Pharmagene, a drug discovery company on a target validation agreement with Schering-Plough Research Institute, the research and development arm of Schering-Plough Corporation, a major pharmaceutical company.

The agreement gives Schering-Plough Research Institute access to the Pharmagene TargetEvaluator® database and permits them to nominate genes to be profiled by Pharmagene in disease-specific human tissues. Pharmagene TargetEvaluator® is a database of information on gene expression in human tissues and forms part of Pharmagene’s target validation capabilities. This is an increasingly important aspect of pharmaceutical research. Financial information about the deal has not been disclosed.

Commenting on the agreement, John Murphy, Group Legal Director of Pharmagene, said: “This agreement is the second subscription to Pharmagene TargetEvaluator® by a major US-based pharmaceutical company. It is also a further endorsement of our approach to target validation and our increasing commercial focus on this key drug discovery marketplace.

“Gene expression information facilitates the identification of gene function. Once a gene’s function has been determined it may be possible to design drugs to moderate the function of that gene, or its protein product, and thereby treat or prevent the disease being investigated. I am pleased to have been working with Clare Whiteway and John Wilkinson on this deal. Their understanding of our business and the issues assisted greatly,” he said.

John Wilkinson, joint head of Bird & Bird’s International Life Sciences Group, commented: “We are delighted to have assisted Pharmagene on this important initiative. We are pleased to continue to advise Pharmagene, and our contribution reflects the strong relationship we have developed with them”.

Bird & Bird has a highly rated life sciences group, having been identified as a leader in its field by Global Counsel.

For any more information, please contact John Wilkinson on +44 (0) 20 7415 6000 or Larry Cattle on + 44 (0) 20 7415 6000.